World Orphan Drug Congress
The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.
The World Orphan Drug Congress is the largest and most established orphan drugs & rare diseases meeting of its kind across the globe.
This panel will discuss what the legislation brings, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version, that it works for both, the biotech ecosystem, maintaining innovation pipelines, and patients.
Event agenda 12:00: Registration opens 12:30: Panel starts 13:45: Panel close and networking lunch 15:00: Close Confirmed Speakers Tomislav Sokol MEPMember SANT Committee, European Parliament Hilde […]
Join our very own Healthcare Policy Senior Manager, Adrien Samson in Madrid where he will be speaking in the panel "Innovation, Funding and Access to Orphan Drugs: Challenges and Opportunities" between 12:15 and 13:00.
Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies.
Against the backdrop of the Belgian EU Council Presidency, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations, industry and policy to […]
We are thrilled to announce that AseBio will hold the fifth edition of the AseBio Investor Day at the gorgeous Kursaal conference center in San Sebastián […]
Get ready for the touchdown of Europe's finest life sciences conference, Knowledge for Growth, on May 16, 2024, in the vibrant city of Antwerp, Belgium!Elevate your […]
Explore how industrial biotechnologies can achieve Europe’s environmental ambitions. Discussions will centre on exploring both regulatory frameworks and technological advancements, identifying our core strengths and opportunities, […]
Over the millennia science & technology have steadily advanced, but key unsolved challenges remain, and much more is possible. The Curious – Future Insight™ Conference brings […]
Join our Director General Dr Claire Skentelbery on 2 October 2024 where she will be speaking at the Novartis & BritCham event "Enhancing Europe’s Pharma and […]
EuropaBio is pleased to partner with CPHI Milan 2024, the biggest international pharmaceutical industry event for the thirty fifth anniversary edition. This year's edition held from […]
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.